FM101 explained

FM101 is a selective adenosine A3 receptor modulator developed for various indications, including glaucoma and non-alcoholic fatty liver disease.[1] [2] [3]

Notes and References

  1. Jayanetti . Viran . Sandhu . Sartaj . Lusthaus . Jed A. . The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma . Journal of Experimental Pharmacology . 20 November 2020 . 12 . 539–548 . 10.2147/JEP.S281187 . 33244278 . 7685378 . free .
  2. Park . JeongSu . Choi . Su-Yeon . Wang . Feng . Park . Chong-Woo . Lee . Jiyoun . Lee . Hyuk-Woo . Roh . Yoon-Seok . Imbalance Between α1-Antitrypsin and Neutrophil Elastase in Simple Steatosis Promotes Inflammation and Fibrosis Through Regulation of Adenosine a3 Receptor Signaling in Non-alcoholic Steatohepatitis . The FASEB Journal . April 2020 . 34 . S1 . 1 . 10.1096/fasebj.2020.34.s1.03837. free . 219099467 .
  3. Park . Chong-Woo . Han . Chung-Tack . Sakaguchi . Yasue . Lee . Jiyoun . Youn . Hwa-young . Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis . EXCLI Journal . 12 February 2020 . 19 . 187–200 . 10.17179/excli2019-2058 . 32256265 . 7105940 . 1611-2156.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "FM101".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.